Sellas Life Sciences Stock Soars as Investors Anticipate Future Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 58 minutes ago
0mins
Source: stocktwits
- Investor Confidence Surge: A Stocktwits poll of about 3,600 voters revealed that 74% expect Sellas Life Sciences (SLS) to reach $25 or higher within 12 months, indicating over 60% upside potential from current levels.
- Clinical Trial Progress: The Phase 3 Regal trial has reached 78 of the 80 required events, with CEO Angelos Stergiou stating that the slower event accumulation is a positive signal, suggesting patients may be living longer than expected, which could position GPS as the new standard of care in AML treatment if successful.
- Market Capital Growth: Sellas' market cap has surged from $73 million at the start of 2024 to over $1.5 billion by mid-2026, with a cash balance of $107.1 million at the end of Q1 and an additional $28.7 million raised through warrant exercises, providing flexibility ahead of a catalyst-heavy period.
- Acquisition Rumors Intensify: The approval of a 20 million-share increase to Sellas' 2023 Equity Incentive Plan has fueled acquisition chatter, while adjustments to Stergiou's equity incentive plan have further attracted investor attention, indicating a potential strategic shift in the company's future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLS
Wall Street analysts forecast SLS stock price to fall
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 12.390
Low
7.00
Averages
7.25
High
7.50
Current: 12.390
Low
7.00
Averages
7.25
High
7.50
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sellas Life Sciences Stock Soars as Investors Anticipate Future Growth
- Investor Confidence Surge: A Stocktwits poll of about 3,600 voters revealed that 74% expect Sellas Life Sciences (SLS) to reach $25 or higher within 12 months, indicating over 60% upside potential from current levels.
- Clinical Trial Progress: The Phase 3 Regal trial has reached 78 of the 80 required events, with CEO Angelos Stergiou stating that the slower event accumulation is a positive signal, suggesting patients may be living longer than expected, which could position GPS as the new standard of care in AML treatment if successful.
- Market Capital Growth: Sellas' market cap has surged from $73 million at the start of 2024 to over $1.5 billion by mid-2026, with a cash balance of $107.1 million at the end of Q1 and an additional $28.7 million raised through warrant exercises, providing flexibility ahead of a catalyst-heavy period.
- Acquisition Rumors Intensify: The approval of a 20 million-share increase to Sellas' 2023 Equity Incentive Plan has fueled acquisition chatter, while adjustments to Stergiou's equity incentive plan have further attracted investor attention, indicating a potential strategic shift in the company's future.
See More
SLS and IBRX Seize Opportunities in Biotech Sector
- Biotech Market Performance: The SPDR S&P Biotech ETF (XBI) rose 17% in June, with Sellas Life Sciences (SLS) surging 53% and ImmunityBio (IBRX) gaining 10%, indicating a strong recovery in the biotech sector that has captured investor interest.
- Innovative Treatment Progress: Sellas is conducting a pivotal Phase 3 trial for GPS targeting acute myeloid leukemia (AML), having reached 78 out of 80 events needed for final analysis, suggesting patients may be living longer than expected, which boosts market confidence in its future.
- M&A Activity Expectations: Edison Investment Research notes that M&A activity in the biotech sector may persist due to clearer policies, attractive valuations, and high innovation levels, especially following Sellas's updates on executive severance and change-of-control arrangements, intensifying market speculation about a potential acquisition.
- FDA Support for Innovation: Edison emphasizes the FDA's support for medical innovation, with expectations for continued accelerated review pathways and flexibility, as evidenced by 52 new molecular entities approved in 2025, close to the 10-year average, reflecting a positive regulatory environment.
See More
Biotech Stocks Hit 52-Week Highs Amid Speculation and Trials
- Sellas Life Sciences Surge: Sellas Life Sciences' stock soared 17% to a 52-week high of $12.43 as record short interest and acquisition speculation fueled investor optimism, particularly ahead of a key update from its Phase 3 AML trial.
- Moderna's Pipeline Advances: Moderna's stock rose 12% to $69.29 following its Science Day presentation, where it showcased advancements in cancer, autoimmune, and rare disease therapies, emphasizing its strategic use of AI and automation in drug discovery.
- AbCellera's Major Partnership: AbCellera Biologics' stock climbed over 10% to a two-year high of $7.40 due to its research collaboration with Jazz Pharmaceuticals, which includes $56 million in upfront funding, indicating strong market confidence in their T-cell engager antibody programs.
- Investor Sentiment Optimism: The closing highs for Sellas Life Sciences, Moderna, and AbCellera Biologics on Friday reflect robust investor confidence in biotech firms, particularly those with identifiable near-term clinical events and business catalysts.
See More
Sellas Life Sciences Hits 52-Week High Amid Buyout Speculation
- Stock Surge: Sellas Life Sciences' stock reached a 52-week high of $12.43 on Friday, driven by record short interest and rising acquisition speculation, reflecting strong investor confidence in the company.
- Clinical Trial Update: The company is approaching a key update for its acute myeloid leukemia (AML) clinical trial, with 78 patient deaths recorded, just shy of the final analysis, which is eagerly anticipated by investors.
- Moderna's Innovations: Moderna's stock climbed to $69.29 following its Science Day presentation, showcasing advancements in cancer, autoimmune, and rare disease therapies, while emphasizing its use of AI and automation in drug discovery, solidifying its market position.
- AbCellera Partnership: AbCellera Biologics' stock rose to $7.40 due to its research collaboration with Jazz Pharmaceuticals, which includes $56 million in upfront funding, indicating strong market interest in its multispecific T-cell engager antibodies and potential future milestone payments.
See More
U.S. Stock Futures Rise as Oil Prices Climb Amid Middle East Tensions
- Market Rebound: Following a lower close on Friday, U.S. stock futures rose overnight on Sunday, with S&P 500 futures up 0.45%, Dow futures up 0.22%, and Nasdaq 100 futures up 0.43%, indicating investor optimism ahead of key economic data releases.
- Oil Price Surge: Amid escalating tensions in the Middle East, Brent crude futures rose 0.92% to around $72.65 per barrel, while WTI crude futures climbed about 1% to $69.92, reflecting market concerns over energy supply disruptions.
- Economic Data Focus: This week, markets will closely watch the non-farm payroll report and ISM Manufacturing PMI, as these key economic indicators are expected to significantly influence investor decisions, especially ahead of the holiday.
- Geopolitical Risks: Tensions between the U.S. and Iran have intensified, although both nations agreed to pause attacks and meet in Qatar on Tuesday, the market remains cautious about potential military conflict, impacting investor confidence.
See More
OpenAI Considers Delaying IPO to Next Year Amid Market Volatility
- Market Performance Review: On Friday, the S&P 500 fell by 0.1%, the Nasdaq 100 lost 1.1%, and the Dow Jones slipped 0.1%, indicating a sell-off in megacap tech stocks as investors shifted towards defensive sectors.
- OpenAI IPO Delay: According to The New York Times, OpenAI is considering postponing its IPO to next year, a move that has triggered a retreat in semiconductor equities, primarily due to SpaceX's weak post-debut performance and instability among AI-linked stocks.
- Poor ETF Performance: This week, the VanEck Semiconductor ETF dropped 7.3%, while the SPDR S&P 500 ETF and Invesco QQQ Trust fell by 0.5% and 1.5%, respectively, reflecting a bearish sentiment towards tech stocks.
- Investor Sentiment Shift: Despite the tech sell-off, Mark Hackett from Nationwide noted that the overall U.S. economic health remains strong with robust consumer spending and most corporate earnings exceeding expectations, suggesting that the market may just be undergoing a consolidation phase.
See More
Sellas Life Sciences Stock Soars as Investors Anticipate Future Growth
- Investor Confidence Surge: A Stocktwits poll of about 3,600 voters revealed that 74% expect Sellas Life Sciences (SLS) to reach $25 or higher within 12 months, indicating over 60% upside potential from current levels.
- Clinical Trial Progress: The Phase 3 Regal trial has reached 78 of the 80 required events, with CEO Angelos Stergiou stating that the slower event accumulation is a positive signal, suggesting patients may be living longer than expected, which could position GPS as the new standard of care in AML treatment if successful.
- Market Capital Growth: Sellas' market cap has surged from $73 million at the start of 2024 to over $1.5 billion by mid-2026, with a cash balance of $107.1 million at the end of Q1 and an additional $28.7 million raised through warrant exercises, providing flexibility ahead of a catalyst-heavy period.
- Acquisition Rumors Intensify: The approval of a 20 million-share increase to Sellas' 2023 Equity Incentive Plan has fueled acquisition chatter, while adjustments to Stergiou's equity incentive plan have further attracted investor attention, indicating a potential strategic shift in the company's future.
See More
SLS and IBRX Seize Opportunities in Biotech Sector
- Biotech Market Performance: The SPDR S&P Biotech ETF (XBI) rose 17% in June, with Sellas Life Sciences (SLS) surging 53% and ImmunityBio (IBRX) gaining 10%, indicating a strong recovery in the biotech sector that has captured investor interest.
- Innovative Treatment Progress: Sellas is conducting a pivotal Phase 3 trial for GPS targeting acute myeloid leukemia (AML), having reached 78 out of 80 events needed for final analysis, suggesting patients may be living longer than expected, which boosts market confidence in its future.
- M&A Activity Expectations: Edison Investment Research notes that M&A activity in the biotech sector may persist due to clearer policies, attractive valuations, and high innovation levels, especially following Sellas's updates on executive severance and change-of-control arrangements, intensifying market speculation about a potential acquisition.
- FDA Support for Innovation: Edison emphasizes the FDA's support for medical innovation, with expectations for continued accelerated review pathways and flexibility, as evidenced by 52 new molecular entities approved in 2025, close to the 10-year average, reflecting a positive regulatory environment.
See More
Biotech Stocks Hit 52-Week Highs Amid Speculation and Trials
- Sellas Life Sciences Surge: Sellas Life Sciences' stock soared 17% to a 52-week high of $12.43 as record short interest and acquisition speculation fueled investor optimism, particularly ahead of a key update from its Phase 3 AML trial.
- Moderna's Pipeline Advances: Moderna's stock rose 12% to $69.29 following its Science Day presentation, where it showcased advancements in cancer, autoimmune, and rare disease therapies, emphasizing its strategic use of AI and automation in drug discovery.
- AbCellera's Major Partnership: AbCellera Biologics' stock climbed over 10% to a two-year high of $7.40 due to its research collaboration with Jazz Pharmaceuticals, which includes $56 million in upfront funding, indicating strong market confidence in their T-cell engager antibody programs.
- Investor Sentiment Optimism: The closing highs for Sellas Life Sciences, Moderna, and AbCellera Biologics on Friday reflect robust investor confidence in biotech firms, particularly those with identifiable near-term clinical events and business catalysts.
See More
Sellas Life Sciences Hits 52-Week High Amid Buyout Speculation
- Stock Surge: Sellas Life Sciences' stock reached a 52-week high of $12.43 on Friday, driven by record short interest and rising acquisition speculation, reflecting strong investor confidence in the company.
- Clinical Trial Update: The company is approaching a key update for its acute myeloid leukemia (AML) clinical trial, with 78 patient deaths recorded, just shy of the final analysis, which is eagerly anticipated by investors.
- Moderna's Innovations: Moderna's stock climbed to $69.29 following its Science Day presentation, showcasing advancements in cancer, autoimmune, and rare disease therapies, while emphasizing its use of AI and automation in drug discovery, solidifying its market position.
- AbCellera Partnership: AbCellera Biologics' stock rose to $7.40 due to its research collaboration with Jazz Pharmaceuticals, which includes $56 million in upfront funding, indicating strong market interest in its multispecific T-cell engager antibodies and potential future milestone payments.
See More
U.S. Stock Futures Rise as Oil Prices Climb Amid Middle East Tensions
- Market Rebound: Following a lower close on Friday, U.S. stock futures rose overnight on Sunday, with S&P 500 futures up 0.45%, Dow futures up 0.22%, and Nasdaq 100 futures up 0.43%, indicating investor optimism ahead of key economic data releases.
- Oil Price Surge: Amid escalating tensions in the Middle East, Brent crude futures rose 0.92% to around $72.65 per barrel, while WTI crude futures climbed about 1% to $69.92, reflecting market concerns over energy supply disruptions.
- Economic Data Focus: This week, markets will closely watch the non-farm payroll report and ISM Manufacturing PMI, as these key economic indicators are expected to significantly influence investor decisions, especially ahead of the holiday.
- Geopolitical Risks: Tensions between the U.S. and Iran have intensified, although both nations agreed to pause attacks and meet in Qatar on Tuesday, the market remains cautious about potential military conflict, impacting investor confidence.
See More
OpenAI Considers Delaying IPO to Next Year Amid Market Volatility
- Market Performance Review: On Friday, the S&P 500 fell by 0.1%, the Nasdaq 100 lost 1.1%, and the Dow Jones slipped 0.1%, indicating a sell-off in megacap tech stocks as investors shifted towards defensive sectors.
- OpenAI IPO Delay: According to The New York Times, OpenAI is considering postponing its IPO to next year, a move that has triggered a retreat in semiconductor equities, primarily due to SpaceX's weak post-debut performance and instability among AI-linked stocks.
- Poor ETF Performance: This week, the VanEck Semiconductor ETF dropped 7.3%, while the SPDR S&P 500 ETF and Invesco QQQ Trust fell by 0.5% and 1.5%, respectively, reflecting a bearish sentiment towards tech stocks.
- Investor Sentiment Shift: Despite the tech sell-off, Mark Hackett from Nationwide noted that the overall U.S. economic health remains strong with robust consumer spending and most corporate earnings exceeding expectations, suggesting that the market may just be undergoing a consolidation phase.
See More
